Entyvio is a brand-name drug prescribed for ulcerative colitis and Crohn’s disease. The medication is available as an IV infusion and subcutaneous injection. Entyvio is a biologic drug that’s ...

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing geographic ...

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Deerfield, Ill., May 20, 2014, and Osaka, Japan, May ...

More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerative colitis. The new ...

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...

Please provide your email address to receive an email when new articles are posted on . Entyvio was shown to have low incidence rates of serious infections, infusion-related reactions and malignancies ...

Osaka, JAPAN, October 12, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced interim results from the VISIBLE open-label extension (OLE) study on the long-term ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Entyvio therapy is safe for the long-term treatment of Crohn’s disease and ulcerative colitis, ...

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...

The U.S. Food and Drug Administration today approved Entyvio (vedolizumab) injection to treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn ...